American Journal of Health-System Pharmacy
November 6, 2026
Jeremy W Vandiver, Brandee K Anderson, Takashi L Suyama et al.
Abstract: Purpose: This primer is designed to provide a broad overview of psilocybin and its use in medically supervised settings as part of psychedelic-assisted psychotherapy. This article will act as a framework to give practicing pharmacists the knowledge they need regarding pharmacology, pharmacokinetics, contraindications, adverse effects, and drug interactions that would impact safe use...
American Journal of Health-System Pharmacy
July 13, 2026
Jason To, Heather Cournoyer, Amanda G. Kennedy et al.
PURPOSE To describe a potential emerging neuropsychiatric adverse effect, abnormal dreams or night terrors, associated with atogepant (a calcitonin gene-related peptide receptor antagonist) observed in 4 patients treated at a tertiary headache clinic, and to place these observations in the context of existing postmarketing pharmacovigilance signals. SUMMARY Four patients with migraine developed...
American Journal of Health-System Pharmacy
March 4, 2026
Jennifer E. Thomas, Anna Dellarole, Robin J Jacobs
MDMA and ketamine IV currently have the greatest support in the literature for efficacy in PTSD. Studies suggest treatment with these agents under supervision may lead to improvements in PTSD symptoms, with the medications being generally well tolerated. However, caution should be used when interpreting study results due to limitations such as treatment expectancy effect and the potential for...
American Journal of Health-System Pharmacy
April 22, 2021
Dimitri Ancedy, Maria Sebti, Martine Postaire et al.
7 citations
Ketamine is an anesthetic agent commonly used for the induction of anesthesia. Ketamine is also given to control pain, for treatment of posttraumatic stress disorder, and to induce bronchodilation in refractory asthma. Moreover, ketamine therapy is gaining ground as an intervention for patients with treatment-resistant depression and individuals who have depression with serious suicidal...
American Journal of Health-System Pharmacy
August 20, 2020
Farah Khorassani, Om Talreja
Abstract Purpose To review the efficacy, safety, and place in therapy of intranasal esketamine, a treatment modality for treatment-resistant depression. Summary An electronic literature search of PubMed, MEDLINE, and the ClinicalTrials.gov and Food and Drug Administration (FDA) websites covering the period April 2015 through June 2020 was performed using the following search terms: esketamine,...
American Journal of Health-System Pharmacy
August 1, 2015
Kevin Betthauser, Jeffrey Pilz, Laura E Vollmer
Published evidence regarding the use of cannabis and cannabis derivatives by military veterans with posttraumatic stress disorder (PTSD) is reviewed. When inhaled or delivered orally or transdermally, cannabinoids (the psychoactive components of unrefined marijuana and various derivative products) activate endogenous cannabinoid receptors, modulating neurotransmitter release and producing a...
American Journal of Health-System Pharmacy
February 1, 2005
Peter J. Zed
1 citation
Drug and substance abuse is a major problem in North America. Health care providers who care for patients who abuse drugs and other substances need to have a clear understanding of the health, societal, and economic impact of this problem and an intimate knowledge of the agents of abuse to ensure adequate treatment. Pagliaros' Comprehensive Guide to Drugs and Substances of Abuse was written to...
American Journal of Health-System Pharmacy
June 1, 2002
Kelly M. Smith, Lisa L. Larive, Frank Romanelli
226 citations
The abuse of methylenedioxymethamphetamine (MDMA), flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate (GHB) is discussed. Club drugs are chemical substances used recreationally in social settings. Use is increasingly frequent among young people, especially during all-night dance parties. All four agents have been classified as controlled substances. MDMA ("ecstasy") is available...